ResMed stock has declined in 2026, with reported decreases ranging from 20% to 30%. Despite this decline, some analysts consider the stock undervalued, with some citing a potential fair value. The reason for the decline and whether it presents a buying opportunity are uncertain, with various factors and perspectives being considered.